Circulating microRNAs and Outcome in Patients with Acute Heart FailureReport as inadecuate

Circulating microRNAs and Outcome in Patients with Acute Heart Failure - Download this document for free, or read online. Document in PDF available to download.


The biomarker value of circulating microRNAs miRNAs has been extensively addressed in patients with acute coronary syndrome. However, prognostic performances of miRNAs in patients with acute heart failure AHF has received less attention.


A test cohort of 294 patients with acute dyspnea 236 AHF and 58 non-AHF and 44 patients with stable chronic heart failure CHF, and an independent validation cohort of 711 AHF patients, were used. Admission levels of miR-1-21-23-126-423-5p were assessed in plasma samples.


In the test cohort, admission levels of miR-1 were lower in AHF and stable CHF patients compared to non-AHF patients p = 0.0016. Levels of miR-126 and miR-423-5p were lower in AHF and in non-AHF patients compared to stable CHF patients both p<0.001. Interestingly, admission levels of miR-423-5p were lower in patients who were re-admitted to the hospital in the year following the index hospitalization compared to patients who were not p = 0.0001. Adjusted odds ratio 95% confidence interval for one-year readmission was 0.70 0.53–0.93 for miR-423-5p p = 0.01. In the validation cohort, admission levels of miR-423-5p predicted 1-year mortality with an adjusted odds ratio 95% confidence interval of 0.54 0.36–0.82, p = 0.004. Patients within the lowest quartile of miR-423-5p were at high risk of long-term mortality p = 0.02.


In AHF patients, low circulating levels of miR-423-5p at presentation are associated with a poor long-term outcome. This study supports the value of miR-423-5p as a prognostic biomarker of AHF.

Author: Marie-France Seronde, Mélanie Vausort, Etienne Gayat, Emeline Goretti, Leong L. Ng, Iain B. Squire, Nicolas Vodovar, Malha Sadou



Related documents